ReviewTechnology in cancer research & treatment2011
Using in-vivo fluorescence imaging in personalized cancer diagnostics and therapy, an image and treat paradigm.
Review in Technology in cancer research & treatment, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Advances in Natural-Product-Based Fluorescent Agents and Synthetic Analogues for Analytical and Biomedical Applications.Bioengineering (Basel, Switzerland) · 2024Review
- Recent Advances in the HPPH-Based Third-Generation Photodynamic Agents in Biomedical Applications.International journal of molecular sciences · 2023Review
- Optical Imaging of Triple-Negative Breast Cancer Cells in Xenograft Athymic Mice Using an ICAM-1-Targeting Small-Molecule Probe.Molecular imaging and biology · 2019Article
- Using in vivo fluorescence lifetime imaging to detect HER2-positive tumors.EJNMMI research · 2018Article
- Raman Spectroscopy of Head and Neck Cancer: Separation of Malignant and Healthy Tissue Using Signatures Outside the "Fingerprint" Region.Biosensors · 2017Article
- Spectral triangulation: a 3D method for locating single-walled carbon nanotubes in vivo.Nanoscale · 2016Article
- Quantitative in vivo immunohistochemistry of epidermal growth factor receptor using a receptor concentration imaging approach.Cancer research · 2014Article
- In vivo assessment of HER2 receptor density in HER2-positive tumors by near-infrared imaging, using repeated injections of the fluorescent probe.Technology in cancer research & treatment · 2014Article
- In vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Multiscale BerEp4 molecular imaging of microtumor phantoms: toward theranostics for basal cell carcinoma.Molecular imaging · 2014Article
- Implantable, multifunctional, bioresorbable optics.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- In vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers.PloS one · 2012Article
- Affibody-DyLight conjugates for in vivo assessment of HER2 expression by near-infrared optical imaging.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
The major goal in developing drugs targeting specific tumor receptors, such as Monoclonal AntiBodies (MAB), is to make a drug compound that targets selectively the cancer-causing biomarkers, inhibits their functionality, and/or delivers the toxin specifically to the malignant cells. Recent advances in MABs show that their efficacy depends strongly on characterization of tumor biomarkers. Therefore, one of the main tasks in cancer diagnostics and treatment is to develop non-invasive in-vivo imaging techniques for detection of cancer biomarkers and monitoring their down regulation during the treatment. Such methods can potentially result in a new imaging and treatment paradigm for cancer therapy. In this article we have reviewed fluorescence imaging approaches, including those developed in our group, to detect and monitor Human Epidermal Growth Factor 2 (HER2) receptors before and during therapy. Transition of these techniques from the bench to bedside is the ultimate goal of our project. Similar approaches can be used potentially for characterization of other cancer related cell biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.